Abstract 897P
Background
The early response to concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) is closely correlated with prognosis. In this study, we aimed to predict early response using a combined model that combines sub-regional radiomics features from multi-sequence MRI with clinically relevant factors.
Methods
A total of 104 patients with LA-NPC were randomly divided into training and validation cohorts at a ratio of 3:1. Radiomic features were extracted from subregions within the tumor area using the K-means clustering method, and feature selection was performed using LASSO regression. Four models were established: classical radiomics model, clinical medol, Intratumor Heterogeneity (ITH) score-based model and a fusion model combining ITH score with clinical factors. The predictive performance of these models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).
Results
Among the models, the combined model incorporating ITH score and clinical factors demonstrated the highest predictive performance in the test cohort (AUC = 0.838). Additionally, the models based on ITH score showed superior prognostic value in both the training cohort (AUC = 0.888) and the test cohort (AUC = 0.833).
Conclusions
The combined model that integrates the ITH score with clinical factors exhibited superior performance in predicting early response following concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
Clinical trial identification
Editorial acknowledgement
The authors would like to thank Yuandong Cao, Weilin Xu, and Shu Zhou for their valuable comments and discussions. We also express their gratitude to Jinling Yuan and Mengxing Wu for their assistance with data analysis. This work was supported by the Jiangsu Province Doctoral Start-up Foundation for Entrepreneurship and Innovation (Grant No. 2019303073386ER19) and the Clinical Competence Enhancement Project of Jiangsu Provincial People's Hospital (Grant No. JSPH-MC-2021-17).
Legal entity responsible for the study
The First Affiliated Hospital of Nanjing Medical University.
Funding
Jiangsu Province Entrepreneurship and Innovation Doctoral Talent Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
879P - VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Presenter: Jared Weiss
Session: Poster session 02
880P - Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial
Presenter: Thorsten Fuereder
Session: Poster session 02
881P - Cetuximab with dalpicilib in patients with HPV-negative, anti-PD-1 resistant R/M HNSCC
Presenter: Ju Houyu
Session: Poster session 02
882P - Quitting smoking after diagnosis of head and neck cancer is associated with reduced risk of mortality: A multicentric prospective cohort study
Presenter: Mahdi Sheikh
Session: Poster session 02
883P - Oral rehabilitation after mandibular reconstruction for head and neck malignancy: A multicenter study
Presenter: lise marie Roussel
Session: Poster session 02
884P - Real-world treatment patterns and survival outcomes associated with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A German claims data analysis
Presenter: Thomas Kuhnt
Session: Poster session 02
885P - Different patterns of treatment failure between p16+ and p16- patients affected by oropharyngeal carcinoma (OPC) undergoing (chemo)radiation
Presenter: Riccardo Gili
Session: Poster session 02
887P - Treatment of elderly patients with locally advanced laryngeal carcinoma with dose-intense chemotherapy followed by radio-chemotherapy: Evading surgical intervention
Presenter: Maher Salamoon
Session: Poster session 02
888P - Comparing paclitaxel plus cisplatin versus cisplatin in concurrent chemoradiotherapy for stage IV locoregionally advanced nasopharyngeal carcinoma: A phase II randomized trial
Presenter: Ling Guo
Session: Poster session 02